CN105189491B - 制备葡萄糖基神经酰胺合酶抑制剂的方法 - Google Patents

制备葡萄糖基神经酰胺合酶抑制剂的方法 Download PDF

Info

Publication number
CN105189491B
CN105189491B CN201480026302.4A CN201480026302A CN105189491B CN 105189491 B CN105189491 B CN 105189491B CN 201480026302 A CN201480026302 A CN 201480026302A CN 105189491 B CN105189491 B CN 105189491B
Authority
CN
China
Prior art keywords
formula
compound
alkyl
cycloalkyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480026302.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105189491A (zh
Inventor
C·西格尔
R·吉米
M·里尔登
J·赵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to CN201810630738.4A priority Critical patent/CN108658970A/zh
Publication of CN105189491A publication Critical patent/CN105189491A/zh
Application granted granted Critical
Publication of CN105189491B publication Critical patent/CN105189491B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201480026302.4A 2013-03-15 2014-03-13 制备葡萄糖基神经酰胺合酶抑制剂的方法 Active CN105189491B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810630738.4A CN108658970A (zh) 2013-03-15 2014-03-13 制备葡萄糖基神经酰胺合酶抑制剂的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791913P 2013-03-15 2013-03-15
US61/791,913 2013-03-15
PCT/US2014/025384 WO2014151291A1 (en) 2013-03-15 2014-03-13 Method of preparing glucosylceramide synthase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810630738.4A Division CN108658970A (zh) 2013-03-15 2014-03-13 制备葡萄糖基神经酰胺合酶抑制剂的方法

Publications (2)

Publication Number Publication Date
CN105189491A CN105189491A (zh) 2015-12-23
CN105189491B true CN105189491B (zh) 2018-07-06

Family

ID=50543333

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480026302.4A Active CN105189491B (zh) 2013-03-15 2014-03-13 制备葡萄糖基神经酰胺合酶抑制剂的方法
CN201810630738.4A Pending CN108658970A (zh) 2013-03-15 2014-03-13 制备葡萄糖基神经酰胺合酶抑制剂的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810630738.4A Pending CN108658970A (zh) 2013-03-15 2014-03-13 制备葡萄糖基神经酰胺合酶抑制剂的方法

Country Status (20)

Country Link
US (4) US9682975B2 (https=)
EP (2) EP2970251B1 (https=)
JP (2) JP6543242B2 (https=)
KR (1) KR20150130386A (https=)
CN (2) CN105189491B (https=)
AR (1) AR095436A1 (https=)
AU (2) AU2014235132B2 (https=)
BR (1) BR112015020667A2 (https=)
CA (2) CA2906581C (https=)
CY (1) CY1121859T1 (https=)
DK (1) DK3514157T3 (https=)
ES (2) ES2968073T3 (https=)
HU (2) HUE043394T2 (https=)
IL (2) IL240617B (https=)
MX (2) MX365464B (https=)
RU (1) RU2015144035A (https=)
SG (2) SG10201706575UA (https=)
TW (2) TWI649317B (https=)
UY (1) UY35438A (https=)
WO (1) WO2014151291A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
TWI649317B (zh) 2013-03-15 2019-02-01 健臻公司 製備葡糖基神經醯胺合成酶抑制劑之方法
EP3583653B1 (de) * 2017-02-17 2020-12-16 Westfälische Wilhelms-Universität Münster Elektrolyt-zusatz für lithium-ionen-batterien
JP2021506920A (ja) 2017-12-21 2021-02-22 リソソーマル・セラピューティクス・インコーポレイテッドLysosomal Therapeutics Inc. 結晶性の置換シクロヘキシルピラゾロ[1,5−a]ピリミジニルカルボキサミド化合物およびその治療的使用
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof
CN114040762A (zh) 2019-02-04 2022-02-11 建新公司 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
TW202142236A (zh) 2020-02-03 2021-11-16 美商健臻公司 用於治療與溶體儲積症相關的神經症狀之方法
JP7725076B2 (ja) 2020-04-28 2025-08-19 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン グルコシルセラミド合成酵素のピリジン阻害剤及びそれらを使用する治療方法
KR20230043024A (ko) 2020-07-24 2023-03-30 젠자임 코포레이션 벤글루스타트를 포함하는 제약 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB725228A (en) * 1952-06-19 1955-03-02 Roche Products Ltd Substituted carbamic acid esters and process for the manufacture thereof
CN1063749C (zh) * 1996-02-23 2001-03-28 阿斯特拉公司 用于治疗的氨基甲酸的氮杂双环酯
WO2012175119A1 (en) * 2011-06-22 2012-12-27 Isochem Process for the preparation of solifenacin and salts thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB725226A (en) * 1952-06-03 1955-03-02 Berger Brothers Co Improvements in or relating to an inflatable surgical pad
NL130759C (https=) * 1965-10-07
DE4326510A1 (de) 1993-08-06 1995-02-09 Bayer Ag Verfahren zur Herstellung von Cyclohexen-Derivaten
WO1995021820A1 (en) * 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
JPH08198751A (ja) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
JP5285643B2 (ja) * 2010-03-15 2013-09-11 シャープ株式会社 半導体集積回路および電子情報機器
RU2607084C2 (ru) 2010-11-12 2017-01-10 Сионоги Энд Ко., Лтд. Кристаллы производных 6,7-ненасыщенного-7-карбамоилморфинана и способ их получения
AU2012231275A1 (en) * 2011-03-18 2013-10-17 Genzyme Corporation Glucosylceramide synthase inhibitors
JP2013053228A (ja) * 2011-09-02 2013-03-21 Asahi Kasei E-Materials Corp エポキシ樹脂用硬化剤及びマイクロカプセル型エポキシ樹脂用硬化剤
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
TWI649317B (zh) * 2013-03-15 2019-02-01 健臻公司 製備葡糖基神經醯胺合成酶抑制劑之方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB725228A (en) * 1952-06-19 1955-03-02 Roche Products Ltd Substituted carbamic acid esters and process for the manufacture thereof
CN1063749C (zh) * 1996-02-23 2001-03-28 阿斯特拉公司 用于治疗的氨基甲酸的氮杂双环酯
WO2012175119A1 (en) * 2011-06-22 2012-12-27 Isochem Process for the preparation of solifenacin and salts thereof

Also Published As

Publication number Publication date
US20160039806A1 (en) 2016-02-11
AU2014235132B2 (en) 2018-08-02
EP3514157A1 (en) 2019-07-24
US9682975B2 (en) 2017-06-20
EP3514157B1 (en) 2023-09-06
DK3514157T3 (da) 2023-11-27
JP6813626B2 (ja) 2021-01-13
SG10201706575UA (en) 2017-09-28
CA2906581A1 (en) 2014-09-25
EP2970251A1 (en) 2016-01-20
US20190031652A1 (en) 2019-01-31
HK1220689A1 (en) 2017-05-12
US20200181137A1 (en) 2020-06-11
TW201900625A (zh) 2019-01-01
KR20150130386A (ko) 2015-11-23
HUE043394T2 (hu) 2019-08-28
CA2906581C (en) 2022-09-20
MX365464B (es) 2019-06-04
WO2014151291A1 (en) 2014-09-25
UY35438A (es) 2014-10-31
IL240617A0 (en) 2015-10-29
RU2015144035A (ru) 2017-04-20
EP2970251B1 (en) 2019-02-27
US20170334903A1 (en) 2017-11-23
TWI649317B (zh) 2019-02-01
AU2014235132A1 (en) 2015-09-24
JP2016512838A (ja) 2016-05-09
JP2019167379A (ja) 2019-10-03
US10065949B2 (en) 2018-09-04
US10604518B2 (en) 2020-03-31
IL259770B (en) 2020-04-30
CY1121859T1 (el) 2020-07-31
ES2968073T3 (es) 2024-05-07
CA3092901C (en) 2024-01-02
CA3092901A1 (en) 2014-09-25
JP6543242B2 (ja) 2019-07-10
AR095436A1 (es) 2015-10-14
HUE064200T2 (hu) 2024-02-28
IL240617B (en) 2019-08-29
CN108658970A (zh) 2018-10-16
AU2019200350A1 (en) 2019-02-07
US10954230B2 (en) 2021-03-23
BR112015020667A2 (pt) 2017-07-18
ES2727869T3 (es) 2019-10-21
IL259770A (en) 2018-07-31
RU2015144035A3 (https=) 2018-03-01
MX389168B (es) 2025-03-20
TW201524974A (zh) 2015-07-01
SG11201506415XA (en) 2015-09-29
CN105189491A (zh) 2015-12-23
MX2015012842A (es) 2016-02-03

Similar Documents

Publication Publication Date Title
CN105189491B (zh) 制备葡萄糖基神经酰胺合酶抑制剂的方法
EP3590920B1 (en) 2-(substituted benzene matrix) aromatic formate fto inhibitor, preparation method therefor, and applications thereof
KR20110117215A (ko) 5-원 헤테로시클릭 화합물의 아자스피라닐-알킬카르바메이트의 유도체, 그의 제조법, 및 그의 치료 용도
KR20150011003A (ko) Lpar 길항제로서 치환된 피라졸 화합물
KR102029516B1 (ko) 아자 아다만탄의 유도체 및 이의 용도
US9938282B2 (en) Expedient synthesis of sitagliptin
JP2020019786A (ja) オキシンドール化合物およびその医薬組成物
WO2012038904A1 (fr) Derives de nicotinamide, leur preparation et leur application en therapeutique
HK40012168A (en) Method of preparing glucosylceramide synthase inhibitors
HK40012168B (en) Method of preparing glucosylceramide synthase inhibitors
HK1220689B (en) Method of preparing glucosylceramide synthase inhibitors
CN114591337A (zh) 一种吡唑并[1,2-a][1,2,4]三嗪-3,6-二酮衍生物及其制备方法
HK1181384A1 (en) Method for producing substituted pyridin-2-one
HK1181384B (en) Method for producing substituted pyridin-2-one

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant